{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:19:07Z","timestamp":1787847547962,"version":"build-2784847793"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Inflammatory bowel disease is a group of chronic recurrent diseases in the digestive tract, including ulcerative colitis and Crohn\u2019s disease. Over the past few decades, the treatment of IBD has made great progress but there is still a lot of room for improvement. Hyperbaric oxygen therapy (HBOT) was defined as the therapeutic effect of inhaling 100% oxygen higher than one atmosphere and reported to be used in stroke, decompression sickness and wound healing. Since several authors reported the role of HBOT as an adjunct to conventional medical treatment in patients with refractory IBD, the relevant research has shown an increasing trend in recent years. Clinical and experimental studies have revealed that HBOT may exert its therapeutic effect by inhibiting inflammation and strengthening the antioxidant system, promoting the differentiation of colonic stem cells and recruiting cells involved in repair. The purpose of this review is to summarize the past clinical and experimental studies and to understand the impact of HBOT in the treatment of IBD more deeply. In addition, we also hope to provide some ideas for future clinical and research work.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2045-9912.311497","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T04:55:10Z","timestamp":1616043310000},"page":"66-71","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["The role of hyperbaric oxygen therapy in inflammatory bowel disease"],"prefix":"10.4103","volume":"11","author":[{"given":"Xin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240907","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R2-5-20240907","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R3-5-20240907","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"R4-5-20240907","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: drug levels and disease activity","volume":"11","author":"Ben-Horin","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R5-5-20240907","first-page":"359","article-title":"Management of inflammatory bowel disease in poor responders to infliximab","volume":"7","author":"Guerra","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"R6-5-20240907","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.freeradbiomed.2019.04.031","article-title":"Tissue-specific role of Nrf2 in the treatment of diabetic foot ulcers during hyperbaric oxygen therapy","volume":"138","author":"Dhamodharan","year":"2019","journal-title":"Free Radical Biol Med"},{"key":"R7-5-20240907","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.biopha.2018.10.142","article-title":"Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections","volume":"109","author":"Memar","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R8-5-20240907","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-9912-4-18","article-title":"Hyperbaric oxygen therapy applied research in traumatic brain injury: from mechanisms to clinical investigation","volume":"4","author":"Wang","year":"2014","journal-title":"Med Gas Res"},{"key":"R9-5-20240907","doi-asserted-by":"crossref","first-page":"E811","DOI":"10.1152\/ajpendo.2000.278.5.E811","article-title":"Hyperbaric oxygen treatment attenuates cytokine induction after massive hemorrhage","volume":"278","author":"Yamashita","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R10-5-20240907","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1097\/MIB.0b013e31828dcaaf","article-title":"The inflammatory tissue microenvironment in IBD","volume":"19","author":"Colgan","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R11-5-20240907","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1053\/j.gastro.2011.01.056","article-title":"Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis","volume":"140","author":"Glover","year":"2011","journal-title":"Gastroenterology"},{"key":"R12-5-20240907","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0016-5085(89)90649-5","article-title":"Healing of severe perineal and cutaneous Crohn\u2019s disease with hyperbaric oxygen","volume":"97","author":"Brady","year":"1989","journal-title":"Gastroenterology"},{"key":"R13-5-20240907","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bpg.2004.01.003","article-title":"The contribution of HLA genes to IBD susceptibility and phenotype","volume":"18","author":"Yap","year":"2004","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R14-5-20240907","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gut.2004.047092","article-title":"Increased gut permeability in Crohn\u2019s disease: is TNF the link?","volume":"53","author":"Gibson","year":"2004","journal-title":"Gut"},{"key":"R15-5-20240907","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000442932","article-title":"High altitude journeys, flights and hypoxia: any role for disease flares in IBD patients?","volume":"34","author":"Vavricka","year":"2016","journal-title":"Dig Dis"},{"key":"R17-5-20240907","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1479-666X(04)80094-5","article-title":"Perianal Crohn\u2019s disease and infliximab therapy","volume":"2","author":"McNamara","year":"2004","journal-title":"Surgeon"},{"key":"R18-5-20240907","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00000658-193811000-00007","article-title":"Perianal fistulae as a complication of regional ileitis","volume":"108","author":"Penner","year":"1938","journal-title":"Ann Surg"},{"key":"R19-5-20240907","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/MIB.0000000000000315","article-title":"Guidelines for the multidisciplinary management of Crohn\u2019s perianal fistulas: summary statement","volume":"21","author":"Schwartz","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R20-5-20240907","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.giec.2019.02.011","article-title":"Advances in perianal disease associated with Crohn\u2019s disease-evolving approaches","volume":"29","author":"Wang","year":"2019","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"R21-5-20240907","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00004836-199410000-00006","article-title":"Hyperbaric oxygen for perianal Crohn\u2019s disease","volume":"19","author":"Lavy","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"R22-5-20240907","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1023\/A:1027378532003","article-title":"Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn\u2019s disease","volume":"17","author":"Weisz","year":"1997","journal-title":"J Clin Immunol"},{"key":"R23-5-20240907","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00004836-199510000-00010","article-title":"Six patients whose perianal and ileocolic Crohn\u2019s disease improved in the Dead Sea environment","volume":"21","author":"Fraser","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"R24-5-20240907","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1590\/S0102-86502011000800024","article-title":"Crohn\u2019s disease and hyperbaric oxygen therapy","volume":"26 Suppl 2","author":"Iezzi","year":"2011","journal-title":"Acta Cir Bras"},{"key":"R25-5-20240907","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S0102-86502016001300005","article-title":"Adjunctive hyperbaric oxygen therapy promotes successful healing in patients with refractory Crohn\u2019s disease","volume":"31 Suppl 1","author":"Feitosa","year":"2016","journal-title":"Acta Cir Bras"},{"key":"R26-5-20240907","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1111\/j.1572-0241.1999.03374.x","article-title":"Hyperbaric oxygen as adjunct therapy for Crohn\u2019s intractable enteric ulcer","volume":"94","author":"Takeshima","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R27-5-20240907","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF02054120","article-title":"Hyperbaric oxygenation in severe perineal Crohn\u2019s disease","volume":"38","author":"Colombel","year":"1995","journal-title":"Dis Colon Rectum"},{"key":"R28-5-20240907","doi-asserted-by":"crossref","first-page":"FSO77","DOI":"10.4155\/fso.15.77","article-title":"Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn\u2019s disease","volume":"1","author":"Agrawal","year":"2015","journal-title":"Future Sci OA"},{"key":"R29-5-20240907","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/codi.12500","article-title":"Healing under pressure: hyperbaric oxygen and myocutaneous flap repair for extreme persistent perineal sinus after proctectomy for inflammatory bowel disease","volume":"16","author":"Chan","year":"2014","journal-title":"Colorectal Dis"},{"key":"R30-5-20240907","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrgastro.2016.186","article-title":"Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH","volume":"14","author":"Ray","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R31-5-20240907","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000358131","article-title":"An overview of the natural history of inflammatory bowel diseases","volume":"32","author":"Dom\u00e8nech","year":"2014","journal-title":"Dig Dis"},{"key":"R32-5-20240907","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.13491","article-title":"Review article: the practical management of acute severe ulcerative colitis","volume":"43","author":"Seah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-5-20240907","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cgh.2011.07.016","article-title":"Postoperative complications and mortality following colectomy for ulcerative colitis","volume":"9","author":"de Silva","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R34-5-20240907","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.gastro.2015.06.001","article-title":"Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"R35-5-20240907","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004836-200110000-00018","article-title":"Hyperbaric oxygen therapy for severe ulcerative colitis","volume":"33","author":"Buchman","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"R36-5-20240907","first-page":"632","article-title":"A different therapeutic approach in patients with severe ulcerative colitis: hyperbaric oxygen treatment","volume":"96","author":"G\u00fcrb\u00fcz","year":"2003","journal-title":"South Med J"},{"key":"R37-5-20240907","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(97)10187-8","article-title":"Pyoderma gangrenosum","volume":"351","author":"Callen","year":"1998","journal-title":"Lancet"},{"key":"R38-5-20240907","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5217\/ir.2018.16.1.155","article-title":"Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis","volume":"16","author":"Seo","year":"2018","journal-title":"Intest Res"},{"key":"R39-5-20240907","doi-asserted-by":"crossref","first-page":"e000082","DOI":"10.1136\/bmjgast-2016-000082","article-title":"Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series","volume":"3","author":"Bekheit","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R40-5-20240907","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1524-475X.2010.00660.x","article-title":"Vasculogenic stem cell mobilization and wound recruitment in diabetic patients: increased cell number and intracellular regulatory protein content associated with hyperbaric oxygen therapy","volume":"19","author":"Thom","year":"2011","journal-title":"Wound Repair Regen"},{"key":"R41-5-20240907","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41395-018-0005-z","article-title":"Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multicenter, randomized, double-blind, sham-controlled trial","volume":"113","author":"Dulai","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R42-5-20240907","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3109\/00365521.2013.819443","article-title":"Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study","volume":"48","author":"Pagoldh","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"R43-5-20240907","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/2045-9912.184721","article-title":"Hyperbaric oxygen therapy in experimental and clinical stroke","volume":"6","author":"Zhai","year":"2016","journal-title":"Med Gas Res"},{"key":"R44-5-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diabetes.48.1.1","article-title":"Role of oxidative stress in diabetic complications: a new perspective on an old paradigm","volume":"48","author":"Baynes","year":"1999","journal-title":"Diabetes"},{"key":"R45-5-20240907","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2337\/diab.36.9.1014","article-title":"Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat. Effects of insulin treatment","volume":"36","author":"Wohaieb","year":"1987","journal-title":"Diabetes"},{"key":"R46-5-20240907","doi-asserted-by":"crossref","first-page":"493","DOI":"10.33549\/physiolres.930416","article-title":"Effect of hyperbaric oxygen on experimental acute distal colitis","volume":"53","author":"Gulec","year":"2004","journal-title":"Physiol Res"},{"key":"R47-5-20240907","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0016-5085(84)90202-6","article-title":"Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models","volume":"87","author":"Krawisz","year":"1984","journal-title":"Gastroenterology"},{"key":"R48-5-20240907","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s10620-006-3159-2","article-title":"Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acidinduced colitis in rats","volume":"51","author":"Gorgulu","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R49-5-20240907","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10620-007-9956-4","article-title":"Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis","volume":"53","author":"Atug","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R50-5-20240907","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/apt.12753","article-title":"Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease","volume":"39","author":"Dulai","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medical Gas Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.311497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:21:37Z","timestamp":1787844097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.311497"}},"subtitle":["a narrative review"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/2045-9912.311497","relation":{},"ISSN":["2045-9912"],"issn-type":[{"value":"2045-9912","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}